Turn Downtime Into Cash!
He's showing regular people how they can make a killing as traders right from their homes!
Click here to see how.
pixel

Elena Prokupets Insider Information

Director of C4 Therapeutics
The estimated Net Worth of Elena Prokupets is at least  $5.32 Million dollars as of 29 July 2021. Elena Prokupets owns over 15,593 units of C4 Therapeutics stock worth over $4,613,549 and over the last few years Elena sold CCCC stock worth over $701,841.

Elena has made over 1 trades of the C4 Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Elena sold 15,593 units of CCCC stock worth $701,841 on 29 July 2021.

The largest trade Elena's ever made was selling 15,593 units of C4 Therapeutics stock on 29 July 2021 worth over $701,841. On average, Elena trades about 3,898 units every 0 days since 2020. As of 29 July 2021 Elena still owns at least  102,981 units of C4 Therapeutics stock.

How do I contact Elena Prokupets?

The corporate mailing address for Prokupets and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]

Has Elena Prokupets been buying or selling shares of C4 Therapeutics?

In the last ninety days, Elena Prokupets has sold $3,808,396.00 of C4 Therapeutics stock. Most recently, Elena Prokupets sold 54,193 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $48.82, for a transaction totalling $2,645,702.26.

Who are C4 Therapeutics' active insiders?

C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider).

Are insiders buying or selling shares of C4 Therapeutics?

In the last year, C4 Therapeutics insiders bought shares 2 times. They purchased a total of 10,293 shares worth mmore than $195,567.00. In the last year, insiders at the sold shares 13 times. They sold a total of 142,620 shares worth mmore than $6,436,895.58. The most recent insider tranaction occured on September, 15th when Elena Prokupets Director bought 54,193 shares worth more than $2,645,702.26. Insiders at C4 Therapeutics own 21.0 % of the company.

Information on this page was last updated on 9/15/2021.

Elena Prokupets Insider Trading History at C4 Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Sell54,193$48.82$2,645,702.26View SEC Filing Icon  
9/13/2021Sell6,660$50.07$333,466.20View SEC Filing Icon  
9/10/2021Sell2,550$50.00$127,500.00View SEC Filing Icon  
8/2/2021Sell4,257$45.01$191,607.57View SEC Filing Icon  
7/29/2021Sell11,336$45.00$510,120.00View SEC Filing Icon  
See Full Table

Elena Prokupets Buying and Selling Activity at C4 Therapeutics

This chart shows Elena Prokupets's buying and selling at C4 Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

C4 Therapeutics Company Overview

C4 Therapeutics logo
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $49.95
Low: $47.58
High: $50.33

50 Day Range

MA: $42.17
Low: $35.91
High: $49.95

2 Week Range

Now: $49.95
Low: $22.40
High: $50.58

Volume

2,288,026 shs

Average Volume

364,882 shs

Market Capitalization

$2.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Turn Downtime Into Cash!
He's showing regular people how they can make a killing as traders right from their homes!
Click here to see how.
pixel